MagVenture, the Danish medical device company behind MagVenture TMS Therapy, introduces the MagVenture Flow Arm — a patent-pending, clinical positioning system to optimize the delivery of MagVenture’s FDA cleared protocols for non-invasive brain stimulation technology within the treatment of major depressive disorder and as an adjunct therapy for OCD.
Kerry Rome, SVP of Sales, MagVenture, said: “Responsiveness to customer needs is a core part of MagVenture DNA. MagVenture is continuously striving to improve solutions to optimize the clinical practice of transcranial magnetic stimulation – or TMS in short. In recent years, the clinical market for TMS has expanded at such a rapid pace that manufacturers are being challenged to keep pace with the technological requirements emerging with the exponential expansion in the demand for utilization. We’ve seen MagVenture drive an FDA clearance for the ultra-fast ‘Theta Burst’ TMS which has reduced treatment times for patients from 37 to just 3 minutes. Now, with the introduction of a remarkedly smooth solution to help TMS operators quickly and easily prepare patients for treatment, MagVenture is further improving the efficiency and experience of TMS for patients and operators alike.”
The latest improvement to the MagVenture TMS Therapy system deemed the ‘MagVenture Flow Arm’, concerns the applicator ‘coil’. The coil is essentially two very heavy spools of copper wire that produce and focus the magnetic fields for the non-invasive brain stimulation technique. The typically large and unwieldy coils, by necessity, have to be accurately positioned and held immobile over the brain target(s) during the TMS procedures.
Kerry Rome added: “Throughout the R&D and testing phases for the Flow Arm project, the MagVenture organization here in the US has been waiting with much anticipation and, finally, we are super excited about the introduction of MagVenture’s patent-pending ‘Flow Arm’ for TMS coil positioning. It’s a game-changer for TMS providers seeking optimal ease of use and efficiency in their clinical TMS services and, in context with the current COVID-19 pandemic, the improvements in the MagVenture reduced treatment/operator-patient interaction time is going to prove to be a big positive.”
Transcranial Magnetic Stimulation is a technology that applies rapidly changing magnetic fields to stimulate specific areas in the brain. MagVenture TMS Therapy is FDA cleared as a treatment for major depressive disorder (MDD) and as an adjunct therapy treatment for obsessive-compulsive disorder (OCD). MagVenture TMS Therapy is an outpatient procedure with a well-tolerated safety profile with no systemic side effects. The most common side effects are headaches and nausea.
